radiomedix logo
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors
January 10, 2018 05:00 ET | RadioMedix Inc.
Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
radiomedix logo
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
June 22, 2017 16:00 ET | RadioMedix Inc.
Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) --  RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial  evaluating the biodistribution...
radiomedix logo
RadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212
November 01, 2016 01:00 ET | RadioMedix Inc.
Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston TX) and AREVA Med (Plano TX) announced today that they have been awarded a collaborative Small Business Innovation...
Harry LaRosiliere.jpg
AREVA Med Inaugurates Second Lead-212 Production Facility
April 13, 2016 15:22 ET | AREVA Med
PLANO, Texas, April 13, 2016 (GLOBE NEWSWIRE) -- AREVA Med has launched operations at its second high-purity lead-212 (212Pb) production facility located in Plano, Texas. Known as the DDPU (Domestic...
AREVA Med Partners W
AREVA Med Partners With Art Institute of Dallas (U.S.) and École Supérieure de Design Troyes (France)
February 29, 2016 13:30 ET | AREVA Med
PLANO, Texas, Feb. 29, 2016 (GLOBE NEWSWIRE) -- AREVA Med, with roots in France and the U.S., has selected two top design schools – French École Supérieure de Design Troyes and U.S. Art Institute...